- Home
- VRNT vs PRAX Comparison
VRNT vs PRAX Comparison
Compare VRNT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- PRAX
- Stock Information
- Founded
- VRNT 1994
- PRAX 2015
- Country
- VRNT United States
- PRAX United States
- Employees
- VRNT N/A
- PRAX N/A
- Industry
- VRNT EDP Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- PRAX Health Care
- Exchange
- VRNT Nasdaq
- PRAX Nasdaq
- Market Cap
- VRNT 1.5B
- PRAX 1.4B
- IPO Year
- VRNT N/A
- PRAX 2020
- Fundamental
- Price
- VRNT $24.29
- PRAX $74.49
- Analyst Decision
- VRNT Buy
- PRAX Strong Buy
- Analyst Count
- VRNT 7
- PRAX 9
- Target Price
- VRNT $35.67
- PRAX $149.00
- AVG Volume (30 Days)
- VRNT 442.7K
- PRAX 375.8K
- Earning Date
- VRNT 03-26-2025
- PRAX 03-04-2025
- Dividend Yield
- VRNT N/A
- PRAX N/A
- EPS Growth
- VRNT 2980.37
- PRAX N/A
- EPS
- VRNT 0.95
- PRAX N/A
- Revenue
- VRNT $920,749,000.00
- PRAX $1,605,000.00
- Revenue This Year
- VRNT $4.50
- PRAX N/A
- Revenue Next Year
- VRNT $4.50
- PRAX N/A
- P/E Ratio
- VRNT $25.33
- PRAX N/A
- Revenue Growth
- VRNT 4.45
- PRAX N/A
- 52 Week Low
- VRNT $21.28
- PRAX $33.01
- 52 Week High
- VRNT $38.17
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- VRNT 37.65
- PRAX 42.80
- Support Level
- VRNT $25.48
- PRAX $76.00
- Resistance Level
- VRNT $26.62
- PRAX $91.83
- Average True Range (ATR)
- VRNT 0.87
- PRAX 6.29
- MACD
- VRNT -0.08
- PRAX -1.10
- Stochastic Oscillator
- VRNT 12.46
- PRAX 2.42
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries helps brands provide Boundless Customer Engagement. The company's solutions help iconic brands close the gap created when it lacks the resources required to deliver experiences that fulfill customer expectations. Geographically, it derives a majority of its revenue from the United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.